Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
<< anterior 21 a 40 de 57 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes. FDA U.S. Food and Drug Administration 2015:16 de diciembre. [Ref.ID 99736]
22. Cita con resumen
Anónimo. Alirocumab (Praluent) to lower LDL-cholesterol. Med Lett Drugs Ther 2015;57:113-5. [Ref.ID 99651]
23. Cita con resumen
Kesselheim AS, Laggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA 2015;314:27 de octubre. [Ref.ID 99526]
24. Cita con resumen
Anónimo. Google’s life sciences division to work with Sanofi on better ways to manage diabetes. DIA Daily 2015:1 de septiembre. [Ref.ID 99429]
25.Tiene citas relacionadas Cita con resumen
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Ismail HIHM, Reynales H, Limkittikul K, Rivera-Medina HN, Bouchenooghe TA, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, for the CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195-206. [Ref.ID 99178]
26. Cita con resumen
Young K. FDA advisers recommend first-in-class cholesterol-lowering meds. Journal Watch 2015:11 de junio. [Ref.ID 99172]
27. Cita con resumen
Anónimo. Bloomberg: pharma use of matchbacks for digital marketing raises concerns. DIA Daily 2014:10 de diciembre. [Ref.ID 98385]
28. Cita con resumen
Anónimo. Firms pay $67.5 million for special voucher for faster FDA review. DIA Daily 2014:31 de julio. [Ref.ID 97753]
29. Cita con resumen
Anónimo. Lilly looking into claims of bribing Chinese doctors. DIA Daily 2013:23 de agosto. [Ref.ID 95893]
30. Cita con resumen
Anónimo. Glaxo says executives may have violated Chinese law. DIA Daily 2013:23 de julio. [Ref.ID 95774]
31. Cita con resumen
Laurance J. Genzyme restores some access to MS drug after neurologists protest. BMJ 2013;346:1. [Ref.ID 94921]
32. Cita con resumen
Anónimo. FDA approves antisense therapy for HoFH. DIA Daily 2013:31 de enero. [Ref.ID 94643]
33.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
34.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
35.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
36.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
37. Cita con resumen
Laurance J. Neurologists appeal to health secretary over withdrawal of drug. BMJ 2012;345:2. [Ref.ID 94035]
38. Cita con resumen
Holmes D. Skies darken over drug companies. Lancet 2012;379:1863-4. [Ref.ID 93013]
39. Cita con resumen
Mullard A. Second chance for dronedarone after recent setback?. Lancet 2012;379:601. [Ref.ID 92387]
40. Cita con resumen
Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann J-F, for the LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011;365:2463-72. [Ref.ID 91984]
Seleccionar todas
 
<< anterior 21 a 40 de 57 siguiente >>